Head to Head Survey: Shineco (NASDAQ:SISI) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) and Shineco (NASDAQ:SISI) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Recordati Industria Chimica E Farmaceutica and Shineco, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recordati Industria Chimica E Farmaceutica	0	1	0	1	3.00
Shineco	1	0	0	0	1.00

Volatility & Risk

Recordati Industria Chimica E Farmaceutica has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Shineco has a beta of -1.76, meaning that its stock price is 276% less volatile than the S&P 500.

Valuation and Earnings

This table compares Recordati Industria Chimica E Farmaceutica and Shineco”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recordati Industria Chimica E Farmaceutica	$2.96 billion	4.04	$501.92 million	$2.80	20.71
Shineco	$9.60 million	0.00	-$22.45 million	($204.00)	-0.00

Recordati Industria Chimica E Farmaceutica has higher revenue and earnings than Shineco. Shineco is trading at a lower price-to-earnings ratio than Recordati Industria Chimica E Farmaceutica, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Recordati Industria Chimica E Farmaceutica and Shineco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Recordati Industria Chimica E Farmaceutica	18.38%	33.73%	12.76%
Shineco	-380.55%	-79.89%	-33.01%

Institutional and Insider Ownership

4.1% of Shineco shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Recordati Industria Chimica E Farmaceutica beats Shineco on 11 of the 13 factors compared between the two stocks.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.